Tempest FY2025 net loss $26.3M; cash $7.7M; completed CAR-T acquisition

Tempest Therapeutics, Inc.

Net loss improved to $26.3M ($6.33/share) vs $41.8M ($19.50/share) in 2024.
Cash at $7.7M at Dec 31, 2025, down from $30.3M at Dec 31, 2024.
Completed all-stock acquisition of CAR-T assets from Factor Bioscience, including clinical-stage TPST-2003.
TPST-2003 showed 100% CR in 6 evaluable rrMM patients; median PFS 23.1 months in prior IIT.
Raised $2M upfront in March 2026 private placement with up to $4M additional from warrants.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tempest Therapeutics, Inc. reported year ended December 31, 2025 results: net income Net loss and net loss per share for the year were $26.3 million and $6.33, respectively, EPS $6.33.

Period: year ended December 31, 2025
Net income: Net loss and net loss per share for the year were $26.3 million and $6.33, respectively
EPS: $6.33
Result: reported results

Exact text from the filing

from the RDO in June, $3.8 million from the November Offering and $2.8 million from Tempest’s at-the-market offering program. • Net loss and net loss per share for the year were $26.3 million and $6.33, respectively, compared to $41.8 million and $19.50, respectively, for the same period in 2024. • Research and development expenses for the year were $12.6 million

View on SEC.gov

46 earnings releases filed in the last 30 days. Browse all earnings releases →

Tempest Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-130480

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.